No one at the PSA conference disagreed with the meeting's basic premise: that externalization in nearly every aspect of the pharmaceutical business is increasing, both voluntarily and involuntarily as small companies gain increasing development and commercial rights to products they out-license. But there was considerable disagreement on just what needs to be externalized. The philosophical split was evident between companies and within them. The strategic imperative was obvious: drug companies need to assess what they're good at and what they're not. But few companies are honest about that, particularly given the amounts of infrastructure that might need to be cut.
By Roger Longman
No one at the 16th annual Pharmaceutical Strategic Alliances conference disagreed, at least publicly, with the meeting's basic theme and...
Join thousands of industry professionals who rely on In Vivo for daily insights
Already a subscriber?
A look at Novo Nordisk, Eli Lilly and other companies' late-stage clinical studies of GLP-1 drugs in indications ranging from neurodegeneration to oncology, and alcoholic liver disease to autoimmune conditions.
Metsera CEO Whit Bernard applies an unconventional leadership philosophy to develop next-generation obesity therapeutics, including monthly GLP-1 injections and oral peptides.
A Q&A with DeAnn Smith, partner and co-chair of the Patent Trial and Appeal Board Proceedings Practice Group at law firm Foley Hoag.
Advanced AI is revolutionizing sales enablement by addressing training gaps and performance challenges. Used correctly, it can help to bridge the sales-marketing divide, accelerate ramp-up times and provide managers with data-driven insights.
While the adoption of most favored nation drug pricing in the US stands to affect Japanese biopharma firms now heavily reliant on this market, it might also present an opportunity for pricing and policy reforms at home.
Ovid Therapeutics' president and COO Meg Alexander is leading the company’s strategic pivot toward innovative neurological treatments, potentially creating a new class of medicines for rare neurological disorders.
Thijs Spoor's bet on lead-212 is paying off as Perspective Therapeutics advances three clinical programs with promising early efficacy signals and a comprehensive manufacturing strategy.
